This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2005 Aug 16;143(4):313-4.

doi: 10.7326/0003-4819-143-4-200508160-00021.

Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

Caroline Robert, Sandrine Faivre, Eric Raymond, Jean-Pierre Armand, Bernard Escudier

PMID: 16103482
DOI: 10.7326/0003-4819-143-4-200508160-00021

Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

Caroline Robert et al. Ann Intern Med. 2005.

. 2005 Aug 16;143(4):313-4.

doi: 10.7326/0003-4819-143-4-200508160-00021.

Authors

Caroline Robert, Sandrine Faivre, Eric Raymond, Jean-Pierre Armand, Bernard Escudier

PMID: 16103482
DOI: 10.7326/0003-4819-143-4-200508160-00021

No abstract available

PubMed Disclaimer

Similar articles

[Cutaneous side effects of sorafenib and sunitinib].
Autier J, Mateus C, Wechsler J, Spatz A, Robert C. Autier J, et al. Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. doi: 10.1016/j.annder.2007.12.006. Epub 2008 Feb 13. Ann Dermatol Venereol. 2008. PMID: 18342102 Review. French. No abstract available.
Drug essentials. Small molecule multitargeted TKI therapy.
Wilkes GM. Wilkes GM. Oncology (Williston Park). 2008 Oct;22(11 Suppl Nurse Ed):47-8. Oncology (Williston Park). 2008. PMID: 19856581 No abstract available.
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, King AG. Kumar R, et al. Br J Cancer. 2009 Nov 17;101(10):1717-23. doi: 10.1038/sj.bjc.6605366. Epub 2009 Oct 20. Br J Cancer. 2009. PMID: 19844230 Free PMC article.
[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Kondo T. Kondo T. Nihon Jinzo Gakkai Shi. 2012;54(5):574-80. Nihon Jinzo Gakkai Shi. 2012. PMID: 22991835 Review. Japanese. No abstract available.
Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
Sulkes A. Sulkes A. Isr Med Assoc J. 2010 Oct;12(10):628-32. Isr Med Assoc J. 2010. PMID: 21090521 Review.

See all similar articles

Cited by

Sorafenib-associated facial acneiform eruption.
Cohen PR. Cohen PR. Dermatol Ther (Heidelb). 2015 Mar;5(1):77-86. doi: 10.1007/s13555-014-0067-9. Epub 2014 Dec 25. Dermatol Ther (Heidelb). 2015. PMID: 25539704 Free PMC article.
Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer.
Haas NB, Uzzo RG. Haas NB, et al. Curr Treat Options Oncol. 2007 Jun;8(3):211-26. doi: 10.1007/s11864-007-0031-3. Curr Treat Options Oncol. 2007. PMID: 17712534 Review.
Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.
Négrier S, Raymond E. Négrier S, et al. Invest New Drugs. 2012 Aug;30(4):1791-801. doi: 10.1007/s10637-011-9677-6. Epub 2011 May 15. Invest New Drugs. 2012. PMID: 21573959 Review.
Cabozantinib Cutaneous Toxicity-Comprehensive Review.
Tutunaru CV, Alexandru DO, Dracea SA, Ungureanu L, Popa LG, Beiu C. Tutunaru CV, et al. Life (Basel). 2025 Jan 9;15(1):72. doi: 10.3390/life15010072. Life (Basel). 2025. PMID: 39860012 Free PMC article. Review.
Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.
Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, Nanda S, Dahut WL, Cowen EW. Zuo RC, et al. JAMA Dermatol. 2015 Feb;151(2):170-7. doi: 10.1001/jamadermatol.2014.2734. JAMA Dermatol. 2015. PMID: 25427282 Free PMC article. Clinical Trial.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information